The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activationEva Sum(Roche (Switzerland)), Pablo Umaña(Roche (Switzerland))Journal for ImmunoTherapy of CancerMarch 1, 202210.1136/jitc-2021-003264Cited by 24SaveCiteExport RISWatch citationsRelated PapersPD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells|Nature|2022|257Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity|Clinical Cancer Research|2021|62Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1|Research Square|2021|5